Literature DB >> 3037957

Bronchoalveolar neutrophilia during late asthmatic reactions induced by toluene diisocyanate.

L M Fabbri, P Boschetto, E Zocca, G Milani, F Pivirotto, M Plebani, A Burlina, B Licata, C E Mapp.   

Abstract

The mechanism by which late asthmatic reactions are induced by toluene diisocyanate (TDI), a low molecular weight chemical that causes occupational asthma in exposed subjects, is unknown. We investigated whether early and late asthmatic reactions induced by TDI are associated with changes in airway responsiveness to methacholine and airway inflammation as determined by bronchoalveolar lavage. We measured FEV1 before and at regular intervals after exposure to TDI, and performed dose-response curves to methacholine and bronchoalveolar lavage at 8 h after TDI in a group of 6 subjects with late asthmatic reactions and in 6 subjects with only early asthmatic reactions. The same procedure was followed 2 h after TDI in a group of 6 subjects with previously documented late asthmatic reactions and in a group of 6 subjects without any previously documented asthmatic reaction after TDI. In subjects with late asthmatic reactions, neutrophils were increased at both 2 and 8 h, and eosinophils and airway responsiveness were increased only at 8 h. By contrast, neutrophils, eosinophils and airway responsiveness were not increased at 8 h after TDI in subjects with an early asthmatic reaction or at 2 h after TDI in normal control subjects. These results suggest that late asthmatic reactions to TDI, and the associated increase in airway responsiveness, may be caused by airway inflammation.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3037957     DOI: 10.1164/ajrccm/136.1.36

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  35 in total

Review 1.  New aspects of isocyanate asthma.

Authors:  X Baur
Journal:  Lung       Date:  1990       Impact factor: 2.584

2.  Isocyanate-induced asthma: results of inhalation tests with TDI, MDI and methacholine.

Authors:  C Vogelmeier; X Baur; G Fruhmann
Journal:  Int Arch Occup Environ Health       Date:  1991       Impact factor: 3.015

3.  In vitro modulation of the eosinophil-dependent enhancement of the permeability of the bronchial mucosa.

Authors:  C A Herbert; D Edwards; J R Boot; C Robinson
Journal:  Br J Pharmacol       Date:  1991-10       Impact factor: 8.739

4.  Bronchial biopsy evidence for leukocyte infiltration and upregulation of leukocyte-endothelial cell adhesion molecules 6 hours after local allergen challenge of sensitized asthmatic airways.

Authors:  S Montefort; C Gratziou; D Goulding; R Polosa; D O Haskard; P H Howarth; S T Holgate; M P Carroll
Journal:  J Clin Invest       Date:  1994-04       Impact factor: 14.808

5.  Leukotriene B4 and asthma.

Authors:  P E Christie; N C Barnes
Journal:  Thorax       Date:  1996-12       Impact factor: 9.139

6.  Proceedings of the British Pharmacological Society Meeting. Sheffield, 18-20th April 1990.

Authors: 
Journal:  Br J Pharmacol       Date:  1990-06       Impact factor: 8.739

7.  Increase in numbers of CD8 positive lymphocytes and eosinophils in peripheral blood of subjects with late asthmatic reactions induced by toluene diisocyanate.

Authors:  S Finotto; L M Fabbri; V Rado; C E Mapp; P Maestrelli
Journal:  Br J Ind Med       Date:  1991-02

Review 8.  Nedocromil sodium. An updated review of its pharmacological properties and therapeutic efficacy in asthma.

Authors:  R N Brogden; E M Sorkin
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

9.  Inflammatory mediators and cellular infiltration of the lungs in a guinea pig model of the late asthmatic reaction.

Authors:  A F Walls; Y K Rhee; D J Gould; C Walters; C Robinson; M K Church; S T Holgate
Journal:  Lung       Date:  1991       Impact factor: 2.584

Review 10.  Nimesulide in the treatment of patients intolerant of aspirin and other NSAIDs.

Authors:  G E Senna; G Passalacqua; G Andri; A R Dama; M Albano; L Fregonese; L Andri
Journal:  Drug Saf       Date:  1996-02       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.